192 related articles for article (PubMed ID: 37586773)
41. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
42. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
[TBL] [Abstract][Full Text] [Related]
43. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
44. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Takamatsu K; Tanaka N; Hakozaki K; Takahashi R; Teranishi Y; Murakami T; Kufukihara R; Niwa N; Mikami S; Shinojima T; Sasaki T; Sato Y; Kume H; Ogawa S; Kakimi K; Kamatani T; Miya F; Tsunoda T; Aimono E; Nishihara H; Sawada K; Imamura T; Mizuno R; Oya M
Nat Commun; 2021 Sep; 12(1):5547. PubMed ID: 34545095
[TBL] [Abstract][Full Text] [Related]
45. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L; Martinez Chanza N; Farah S; Xie W; Flippot R; Braun DA; Rathi N; Thouvenin J; Collier KA; Seront E; de Velasco G; Dzimitrowicz H; Beuselinck B; Xu W; Bowman IA; Lam ET; Abuqayas B; Bilen MA; Varkaris A; Zakharia Y; Harrison MR; Mortazavi A; Barthélémy P; Agarwal N; McKay RR; Brastianos PK; Krajewski KM; Albigès L; Harshman LC; Choueiri TK
JAMA Oncol; 2021 Dec; 7(12):1815-1823. PubMed ID: 34673916
[TBL] [Abstract][Full Text] [Related]
46. Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
Wald G; Barnes KT; Bing MT; Kresowik TP; Tomanek-Chalkley A; Kucaba TA; Griffith TS; Brown JA; Norian LA
Urol Oncol; 2014 Jul; 32(5):589-600. PubMed ID: 24768357
[TBL] [Abstract][Full Text] [Related]
47. Characterizing the tumor microenvironment in rare renal cancer histological types.
Synnott NC; Poeta ML; Costantini M; Pfeiffer RM; Li M; Golubeva Y; Lawrence S; Mutreja K; Amoreo C; Dabrowska M; Simone G; Pescarmona E; Lenz P; Olanich M; Duggan M; Abubakar M; Fazio VM; Gallucci M; Sentinelli S; Landi MT
J Pathol Clin Res; 2022 Jan; 8(1):88-98. PubMed ID: 34618413
[TBL] [Abstract][Full Text] [Related]
48. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.
Lwu S; Goetz P; Monsalves E; Aryaee M; Ebinu J; Laperriere N; Menard C; Chung C; Millar BA; Kulkarni AV; Bernstein M; Zadeh G
Oncol Rep; 2013 Feb; 29(2):407-12. PubMed ID: 23151681
[TBL] [Abstract][Full Text] [Related]
49. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation.
Stickel JS; Stickel N; Hennenlotter J; Klingel K; Stenzl A; Rammensee HG; Stevanović S
BMC Urol; 2011 Jan; 11():1. PubMed ID: 21251276
[TBL] [Abstract][Full Text] [Related]
50. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
Zeng Q; Zhang W; Li X; Lai J; Li Z
Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
[TBL] [Abstract][Full Text] [Related]
51. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma.
Ingold B; Wild PJ; Nocito A; Amin MB; Storz M; Heppner FL; Moch H
Histopathology; 2008 May; 52(6):674-81. PubMed ID: 18393979
[TBL] [Abstract][Full Text] [Related]
52. Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8
Ning K; Peng Y; Jiang Y; Li Z; Luo X; Lin L; Deng M; Wu Y; Huang T; Huang Y; Xie Y; Yang X; Zhang M; Xiong L; Zou X; Zhou Z; Zhou F; Dong P; Yu C; Zhang Z
Biol Sex Differ; 2023 Sep; 14(1):58. PubMed ID: 37715192
[TBL] [Abstract][Full Text] [Related]
53. Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Liu J; Xu J; Zhang T; Xu K; Bao P; Zhang Z; Xue K; He R; Ma L; Wang Y
Front Immunol; 2022; 13():791158. PubMed ID: 35812372
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
55. Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma.
Chen WJ; Dong KQ; Pan XW; Gan SS; Xu D; Chen JX; Chen WJ; Li WY; Wang YQ; Zhou W; Rini B; Cui XG
Cell Death Dis; 2023 Jan; 14(1):30. PubMed ID: 36646679
[TBL] [Abstract][Full Text] [Related]
56. Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery.
Teh BS; Bloch C; Paulino AC; Shen S; Hinckley L; Baskin D; Butler EB; Amato R
Clin Genitourin Cancer; 2007 Jun; 5(5):334-7. PubMed ID: 17645831
[TBL] [Abstract][Full Text] [Related]
57. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A; Stec R; Szczylik C
Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
[TBL] [Abstract][Full Text] [Related]
58. Metastatic Renal Cell Carcinoma to the Brain: A Contemporary Clinicopathologic Analysis With Comparison of Immunohistochemical Profiles to Selected Primary Brain Tumors With Clear Cell Features.
Zheng W; Goodman AL; Velázquez Vega JE; Yin F; Fung KM; Osunkoya AO
Appl Immunohistochem Mol Morphol; 2020; 28(5):395-402. PubMed ID: 30882396
[TBL] [Abstract][Full Text] [Related]
59. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
[TBL] [Abstract][Full Text] [Related]
60. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
